ICER identifies costliest US drug-price hikes that are not supported by new clinical evidence

ICER

8 October 2019 - In 2017 and 2018, out of nine identified drugs that had substantial price increases on top of already high current spending, seven drugs had no new important evidence to support their price increases.

The Institute for Clinical and Economic Review (ICER) today published its first annual report on Unsupported Price Increases (UPI) of prescription drugs in the United States.

ICER began its analysis by ranking the top 100 drugs by sales revenue in the US. Working with data from SSR Health Inc., drugs were then evaluated to see whether their price increases net of rebates and other concessions were more than twice the level of increase than growth in the medical consumer price index over the 24-month period from the beginning of 2017 to the end of 2018. Ultimately, ICER identified the top ten drugs whose price increases would have contributed to the largest net increase in drug spending in the US. One drug was added to this list following public nomination. ICER then evaluated whether there had been relevant new evidence at any time during the preceding three years that could have supported these price increases.

Read ICER announcement

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Review , Pricing